GlassScriptPhysician profile
Dennis A Buck
NPI 1114157195
$795.44
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.71 · 2020: $15.61 · 2021: $132 · 2022: $224 · 2023: $212 · 2024: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $359 · Education: $23.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $359.44 |
| Education | $23.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $192.98 | 2021-2024 | Tecvayli, Darzalex, Talvey |
| Abbvie INC. | $152.04 | 2024 | |
| Janssen Scientific Affairs, LLC | $120.14 | 2022-2023 | Tecvayli, Darzalex |
| Kyowa Kirin, INC. | $51.50 | 2022-2023 | Poteligeo |
| Celgene Corporation | $51.39 | 2021-2023 | Onureg, Reblozyl |
| Merck Sharp & Dohme LLC | $32.52 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $31.55 | 2021-2023 | Opdualag |
| Pharmacyclics LLC, An Abbvie Company | $22.54 | 2019 | |
| Incyte Corporation | $21.42 | 2023 | Pemazyre, Monjuvi |
| Astrazeneca Pharmaceuticals LP | $20.88 | 2021 | |
| Novartis Pharmaceuticals Corporation | $20.37 | 2023 | |
| Gilead Sciences, INC. | $19.28 | 2022 | |
| Novocure INC. | $18.17 | 2019 | |
| Foundation Medicine, INC. | $18.15 | 2023 | |
| Pfizer INC. | $11.47 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $11.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Buck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.